Fecal test levels refine post-polypectomy surveillance

Objective:

To evaluate whether fecal hemoglobin concentration can refine post-polypectomy surveillance recommendations and reduce colonoscopy demand without increasing colorectal cancer risk.

Key Findings:

• A dose-response relationship was observed between fecal hemoglobin concentration and CRC risk.
• Incidence of CRC increased with higher fecal hemoglobin levels, from 2.2 to 4 cases per 1,000 person-years.
• The fecal hemoglobin-guided approach reduced colonoscopy demand by 9.8% compared to current recommendations.

Interpretation:

Fecal hemoglobin levels can serve as a practical biomarker to optimize surveillance intervals, allowing for longer intervals in low-risk patients and earlier follow-up in high-risk patients.

Limitations:

• The study included only patients with conventional adenomas.
• Limited data on serrated lesions and high-grade dysplasia.
• Non-standardized surveillance practices across centers.

Conclusion:

Integrating fecal hemoglobin concentration into post-polypectomy surveillance can optimize colonoscopy resource allocation without compromising colorectal cancer risk reduction.